http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 07:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html si-local-file:///var/storage/secattach/20260827/26984629.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html Thu, 27 Aug 2026 07:10:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html si-local-file:///var/storage/secattach/20260827/26984629.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html Thu, 27 Aug 2026 07:10:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html si-local-file:///var/storage/secattach/20260827/26984629.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html Thu, 27 Aug 2026 07:10:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282">http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282</a></p> <p> Filed on: August 27, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html Thu, 27 Aug 2026 06:09:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282">http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282</a></p> <p> Filed on: August 27, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html Thu, 27 Aug 2026 06:09:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282">http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282</a></p> <p> Filed on: August 27, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html Thu, 27 Aug 2026 06:09:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380